A Phase 2/3 randomized study of a Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

  • Enrollment

    This study is not currently enrolling.

  • Research Area

    Clinical Cancer Research

  • Sponsor

    0019920593 The Hosp. For Sick Children Study Team